Poolbeg Pharma PLC
POLB
Company Profile
Business description
Poolbeg Pharma PLC is a clinical-stage infectious disease pharmaceutical company, with a novel capital-light clinical model which enables to development of multiple products faster and more cost-effectively than the traditional biotech model. The company aspires to become a one-stop shop for pharma-seeking mid-stage products to license or acquire.
Contact
42 New Road
Queen Mary BioEnterprises Innovation Centre
LondonE1 2AX
GBRT: +44 2071831499
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
10
Stocks News & Analysis
stocks
Market Minute: RBA cuts rates again, US CPI data released
This week, the RBA cut rates after a surprise hold in July; CBA reported earnings ; US inflation data came out, showing its highest reading since February.
stocks
Is the market still overlooking Alibaba’s AI potential?
Despite a 40% share price rally this year, investors could still be underestimating Alibaba’s cloud growth prospects.
stocks
ASX reporting season wrap: CBA, JB Hi-Fi, REA and more
A round up of notable stories and reactions as ASX earnings season gathers steam.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,162.80 | 13.70 | 0.15% |
| CAC 40 | 7,870.34 | 65.37 | 0.84% |
| DAX 40 | 24,377.50 | 191.91 | 0.79% |
| Dow JONES (US) | 44,911.26 | 11.01 | -0.02% |
| FTSE 100 | 9,177.24 | 12.01 | 0.13% |
| HKSE | 25,327.43 | 191.89 | -0.75% |
| NASDAQ | 21,710.67 | 2.47 | -0.01% |
| Nikkei 225 | 42,947.08 | 297.82 | 0.70% |
| NZX 50 Index | 12,880.68 | 46.60 | 0.36% |
| S&P 500 | 6,468.54 | 1.96 | 0.03% |
| S&P/ASX 200 | 8,886.40 | 12.60 | 0.14% |
| SSE Composite Index | 3,674.40 | 7.96 | 0.22% |